

**Tezspire<sup>®</sup> (Tezepelumab-ekko) Prior Authorization Form****Member Name:** \_\_\_\_\_ **Date of Birth:** \_\_\_\_\_ **Member ID#:** \_\_\_\_\_**Drug Information** **Physician billing (HCPCS code:** \_\_\_\_\_)  **Pharmacy billing (NDC:** \_\_\_\_\_)**Dose:** \_\_\_\_\_ **Regimen:** \_\_\_\_\_ **Fill Date:** \_\_\_\_\_**Billing Provider Information****SoonerCare Provider ID:** \_\_\_\_\_ **Provider Name:** \_\_\_\_\_**Provider Phone:** \_\_\_\_\_ **Provider Fax:** \_\_\_\_\_**Prescriber Information****Prescriber NPI:** \_\_\_\_\_ **Prescriber Name:** \_\_\_\_\_**Prescriber Phone:** \_\_\_\_\_ **Prescriber Fax:** \_\_\_\_\_ **Specialty:** \_\_\_\_\_**Clinical Information****For Initial Authorization: Initial approvals will be for the duration of 6 months.**

1. What is the diagnosis for which the medication is being prescribed?  
 Severe Asthma  
 Other: \_\_\_\_\_
2. Will this medication be used as add-on maintenance treatment? Yes \_\_\_ No \_\_\_  
A. If yes, please indicate member's daily medications and dose prescribed for treatment of this diagnosis:  
Drug/Dose: \_\_\_\_\_ Drug/Dose: \_\_\_\_\_
3. Has the member experienced  $\geq$  two asthma exacerbations requiring oral or injectable corticosteroids, or that resulted in hospitalization in the last 12 months? Yes \_\_\_ No \_\_\_  
A. If yes, please indicate dates/details:  
\_\_\_\_\_
4. Has member failed a medium-to-high dose inhaled corticosteroid (ICS) used compliantly within the last 3-6 consecutive months? Yes \_\_\_ No \_\_\_  
A. If yes, please indicate medication/dates: \_\_\_\_\_
5. Has the member failed at least 1 other asthma controller medication used in addition to the medium-to-high dose ICS compliantly for at least the past 3 months? Yes \_\_\_ No \_\_\_  
A. If yes, please indicate medication/dates: \_\_\_\_\_
6. For Tezspire<sup>®</sup> vial or pre-filled syringe, will it be administered by a health care provider prepared to manage anaphylaxis? Yes \_\_\_ No \_\_\_ N/A \_\_\_
7. For Tezspire<sup>®</sup> pre-filled pen, will it be administered by a health care provider prepared to manage anaphylaxis or the member or caregiver has been trained by a health care professional on subcutaneous administration, monitoring for any allergic reactions, and storage of Tezspire<sup>®</sup>? Yes \_\_\_ No \_\_\_ N/A \_\_\_
8. Was Tezspire<sup>®</sup> prescribed by a specialist or has the member been evaluated by a specialist within the last 12 months (or an advanced care practitioner with a supervising physician who is specialist)? Yes \_\_\_ No \_\_\_  
A. If "Yes", please indicate name of specialist: \_\_\_\_\_ Specialty: \_\_\_\_\_

**For Continued Authorization:**

1. Is the member compliant with therapy? Yes \_\_\_ No \_\_\_
2. Is the member responding well to therapy? Yes \_\_\_ No \_\_\_

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

(By signature, the physician confirms the criteria information above is accurate and verifiable in patient records.)

**Pharmacist Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_*Failure to complete this form in full will result in processing delays. Please do not send in chart notes. Specific information will be requested if necessary.***PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:**University of Oklahoma College of Pharmacy  
Pharmacy Management Consultants  
Product Based Prior Authorization Unit  
Fax: 1-800-224-4014  
Phone: 1-800-522-0114 Option 4**CONFIDENTIALITY NOTICE***This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*